Ensayos clínicos

Inclusion Criteria:

• Age ≥ 18 years.
• Any gender.
• Negative urine pregnancy test within 48 hours before the administration of radiopharmaceutical in women under 55.
• Follicular neoplasm or suspicious of follicular neoplasm, cytopathology on biopsy of thyroid nodule.
• Any outside FNA reports are to be reviewed by Mayo pathologist.
• Nodules 1-4 cm with solid appearance on ultrasound.
• Ultrasound images and report documented in medical record, including the size of the nodule and location (upper, mid or lower portion of the thyroid lobe).
• At least 2/3 of either thyroid lobe without nodules should be present to allow for the measurement of uptake in unaffected thyroid tissue.
• Thyroid stimulating hormone (TSH) 0.3-2.0 mIU/L.
• Patient is scheduled or being considered for surgical resection of the nodule.
• I-123 planar and SPECT/CT can be scheduled at least 2-3 days after biopsy and before surgery.

Exclusion Criteria:

• Recent iodinated contrast, including intravenous (IV) and oral CT contrast or interventional vascular or cardiac study (within 6 weeks).
• Hurthle cell adenoma.
• Current thyroid hormone supplementation.
• Current use of anti-thyroid medications (methimazole or propylthiouracyl).
• Less than 2-3 days after thyroid nodule FNA/biopsy.
• Presence of another nodule of similar size in the same area of thyroid lobe, which could impair localization of the nodule on positron emission tomography (PET)/CT images.
• Less than 2/3 of normal thyroid tissue present in either thyroid lobe without nodules.
• Positive pregnancy test.
• All women who are breastfeeding.

Eligibility last updated 3/30/23 to match clinicaltrials.gov. Questions regarding updates should be directed to the study team contact.